Methods and apparatuses for analyzing proteins and other biological materials and xenobiotics within a sample. A specimen is generated, which may include an energy absorbent matrix. The specimen is struck with laser beams such that the specimen releases proteins. The atomic mass of the released proteins over a range of atomic masses is measured. An atomic mass window of interest within the range of atomic masses is analyzed to determine the spatial arrangement of specific proteins within the sample, and those specific proteins are identified as a function of the spatial arrangement. By analyzing the proteins, one may monitor and classify disease within a sample.Australia Patent 2002362961
Angioedema is a life-threatening and unpredictable side effect of angiotensin converting enzyme (ACE) inhibitors and ACE/Neutral endopeptidase (NEP) inhibitors, drugs aimed at reducing cardiovascular mortality associated with a variety of disease states. This technology permits the identification of individuals at risk for developing this angioedemic condition as a result of taking ACE inhibitors or NEP inhibitors. The patents and patent applications claim biological markers, diagnostic methods and kits.
The present invention provides unsaturated choline analogs which, when hyperpolarized, may be useful as MRI contrast agents, and methods of making these choline analogs. These analogs can also be further modified to form hyperpolarized choline for use as an MRI contrast agent. The invention takes advantage of PHIP and can be produced in volume in much shorter times than by using DNP.
The present invention describes clinically-practical MRI methods for distinguishing bound and pore water signals from cortical bone based on T2-selective adiabatic pulses as well as T1 characteristics of cortical bone bound and pore water, and offers an improved method of assessing bone structure and fracture risk over x-ray based diagnostic techniques.
The sheer volume of medical information available to physicians today is overwhelming. Diagnostic Management Team provides a concise, accurate method for ordering the correct diagnostic tests every time, and it returns the results in a uniform report format, easily read by the physician. This has already been launched within Vanderbilt University, with a high adoption rate amongst physicians and has already shown significant savings.
Vanderbilt Medical Center researchers have developed a non-invasive and reproducible method of assessing right-ventricular function using contrast-echocardiography. The right-ventricular transit time (RVTT) measures the time needed for echocardiographic contrast to travel from the RV to the bifurcation of the main pulmonary artery. Coupled with the pulmonary transit time (PTT), the time needed for contrast to traverse the entire pulmonary circulation, RVTT is part of a family of diagnostic parameters that can report on RV-specific performance as well as the RV's function relative to that of the pulmonary circuit as a whole.
Premature birth is the leading cause of neonatal death worldwide, affecting 13% of US infants (500,000 babies/year). Of great concern, premature birth cannot currently be reliably predicted or prevented. Existing risk factors and interventions for premature birth focus solely on maternal factors, thereby overlooking paternal factors that influence an infant's development. Vanderbilt researchers have now identified a missing piece of the puzzle and are developing a diagnostic test to predict premature birth risks conferred to infants by their fathers. Of key importance, the test offers meaningful clinical guidance, as risk factors measured by the diagnostic can be modified before conception via supplementation.
Dr. Fernando P. Polack, a leading international researcher in pediatric infectious diseases, has discovered a new prognostic to predict which infants are at high-risk for hospitalization caused by severe Respiratory Syncytial Virus (RSV) infections. The test measures a mutation in a single gene, along with a quantifiable environmental factor that confers susceptibility. The goal is to categorize infants most likely to benefit from preventative care.
The overall lifetime colorectal cancer risk for Americans is 5.1%, thus screening is recommended for those over the age of 50. Currently, colonoscopies are the standard for monitoring colon cancer development, but are invasive. Therefore, a need exists for a minimally-invasive test that could measure colon cancer risk. Ideally, such a test would offer a straightforward, personalized recommendation on how to substantially reduce colorectal cancer risk. Researchers at Vanderbilt University have identified a test that can characterize colorectal cancer risk and recommend a strategy for risk reduction. Importantly, this test requires only a blood sample and information about a person's diet.
A Vanderbilt research group has discovered a diagnostic to identify patients with non-small cell lung cancer that would respond to MEK inhibitor therapies. This diagnostic indirectly measures loss of tumor suppressor activity by the protein LKB1. The traditional approach to determine MEK inhibitor sensitivity, which is measurement of LKB1 mutations, misses 50% of patients who would benefit from these drugs. This diagnostic measures expression of a small panel of genes to identify a larger population that is sensitive to MEK inhibition.